Soluble Ve cadherin ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 1 |
51. Scleroderma
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02212249 (ClinicalTrials.gov) | May 2014 | 23/4/2014 | Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis | Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis | Primary Raynaud Disease;Systemic Sclerosis | Biological: soluble Ve cadherin | University Hospital, Grenoble | NULL | Completed | 18 Years | N/A | Both | 85 | N/A | France |